However, doctors differ in their views on testing before prescribing ... Slamon points out that the two pathways are linked. When HER2 is amplified, “one of the pathways that consistently ...
The new diagnostic, part of Roche’s Ventana platform, has been approved in the US under the Pathway brand since October 2022. In Europe, it is called the Ventana HER2 (4B5) test – already used ...
Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
The PATHWAY HER2 (4B5) test has now received approval to identify a new patient population designated as "HER2-ultralow." HER2-ultralow refers to patients who have very low levels of HER2 expression, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback